<i>ERBB2</i> /HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer

20254 citationsJournal Article

Authors

Gillian Vandekerkhove · BC Cancer Agency

Andrew J. Murtha · University of British Columbia

David C. Müller · University of British Columbia

Maria Stephenson · University of British Columbia

Kimia Rostin · University of British Columbia

Aslı D. Munzur · University of British Columbia

Carlos Vasquez-Rios

Abstract

We report a combined analysis of HER2 IHC and ERBB2 genotype in mUC ctDNA and archival tissue, revealing high spatiotemporal heterogeneity. Our data suggest that sole reliance on DNA- or protein-based HER2 assessment is insufficient to capture nuanced genomic indicators of HER2 pathway reliance and support a role for ctDNA alongside existing methods for characterizing HER2/ERBB2 status during biomarker development in mUC.

Topics & Keywords

Bladder and Urothelial Cancer Treatments Cancer Genomics and Diagnostics Lung Cancer Treatments and Mutations

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 31, Issue 17, pp. 3725-3741

DOI: 10.1158/1078-0432.ccr-24-3912

Field-Weighted Citation Impact: 7.83